Related Experiment Video
Updated: Aug 31, 2025
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Pathophysiology of Methicillin-Resistant Staphylococcus aureus Superinfection in COVID-19 Patients
Gul Habib1, Khalid Mahmood2, Haji Gul3
1Department of Microbiology, Abbottabad University of Science and Technology, Havelian, Abbottabad 22010, Pakistan.
Abstract:
The global spread of the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has infected humans in all age groups, deteriorated host immune responses, and caused millions of deaths. The reasons for individuals succumbing to COVID-19 were not only the SARS-CoV-2 infection but also associated bacterial infections. Antibiotics were largely used to prevent bacterial infections during COVID-19 illness, and many bacteria became resistant to conventional antibiotics. Although COVID-19 was considered the main culprit behind the millions of deaths, bacterial coinfections and superinfections were the major factors that increased the mortality rate in hospitalized patients. In the present study, we assessed the pathophysiology of methicillin-resistant Staphylococcus aureus (MRSA) superinfection in COVID-19 patients in Pakistan. A total of 3492 COVID-19 hospitalized patients were screened among which 224 strain were resistant to methicillin; 110 strains were tazobactam-resistant; 53 strains were ciprofloxacin-resistant; 23 strains were gentamicin-resistant; 11 strains were azithromycin-resistant; 3 strains were vancomycin-resistant. A high frequency of MRSA was detected in patients aged ≥50 with a prevalence of 7.33%, followed by patients aged >65 with a prevalence of 5.48% and a 5.10% prevalence in patients aged <50. In addition, pneumonia was detected in the COVID-19-associated MRSA (COVID-MRSA) that showed decreased levels of lymphocytes and albumin and increased the mortality rate from 2.3% to 25.23%. Collectively, an MRSA superinfection was associated with increased mortality in COVID-19 after 12 to 18 days of hospitalization. The study assessed the prevalence of MRSA, mortality rate, pneumonia, and the emergence of antibiotic resistance as the main outcomes. The study summarized that COVID-MRSA aggravated the treatment and recovery of patients and suggested testing MRSA as critical for hospitalized patients.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) superinfections significantly increased mortality in hospitalized COVID-19 patients, particularly those over 50. Early MRSA testing is critical for improving patient outcomes and recovery.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Microbiology
Background:
- Coronavirus disease 2019 (COVID-19) mortality is exacerbated by bacterial coinfections and superinfections.
- Widespread antibiotic use during COVID-19 has led to increased bacterial resistance.
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat as a superinfecting agent.
Purpose of the Study:
- To assess the prevalence and pathophysiology of MRSA superinfection in COVID-19 patients in Pakistan.
- To determine the impact of MRSA superinfection on mortality rates and clinical outcomes in COVID-19 patients.
- To investigate the emergence of antibiotic resistance in MRSA strains co-infecting COVID-19 patients.
Main Methods:
- Screened 3492 hospitalized COVID-19 patients for MRSA.
- Identified antibiotic resistance patterns, including resistance to tazobactam, ciprofloxacin, gentamicin, azithromycin, and vancomycin.
- Analyzed patient demographics, clinical data (pneumonia, lymphocyte and albumin levels), and mortality rates.
Main Results:
- A prevalence of 224 MRSA strains was detected among screened COVID-19 patients.
- Higher MRSA prevalence was observed in patients aged ≥50 (7.33%), >65 (5.48%), and <50 (5.10%).
- COVID-19-associated MRSA (COVID-MRSA) patients exhibited pneumonia, decreased lymphocytes/albumin, and a mortality increase from 2.3% to 25.23%, with higher mortality 12-18 days post-hospitalization.
Conclusions:
- MRSA superinfection significantly elevates mortality risk in hospitalized COVID-19 patients.
- COVID-MRSA complicates patient treatment and recovery, necessitating vigilant monitoring.
- Routine screening for MRSA in hospitalized COVID-19 patients is crucial for timely intervention and improved survival.
Related Concept Videos
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:29Pneumonia II: Pathophysiology
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:25Urinary Tract Infection II: Pathophysiology
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.